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ABSTRACT
Introduction: Vancomycin (VAN) failures
associated with the treatment of complicated
methicillin-resistant Staphylococcus aureus
(MRSA) infections have been well described.
The reported ‘‘seesaw effect’’ demonstrates
improved b-lactam activity when VAN and/or
daptomycin (DAP) susceptibility decreases.
However, there are minimal data comparing
ceftaroline (CPT) susceptibility with these
agents or teicoplanin (TEI). Therefore, to
further explore the seesaw effect, we evaluated
the relationship between CPT and VAN, TEI,
and DAP susceptibilities.
Methods: One hundred and fifty clinical MRSA
isolates from the Anti-Infective Research
Laboratory (Detroit, MI, USA) from 2008 to
2012 were analyzed. VAN, TEI, DAP and CPT
minimum inhibitory concentrations (MIC)
were determined via Etest methodology.
MIC50 and MIC90 were calculated for each
antibiotic. Additionally, four isogenic strain
pairs were randomly selected for evaluation by
time–kill methodology for the potential of
enhanced killing by CPT as MICs increased to
VAN, TEI, and DAP.
Results: CPT MICs were inversely correlated
with VAN, DAP, and TEI MICs with correlation
coefficients of -0.535, -0.483, and -0.386,
respectively (P B 0.05). Comparison of the MIC
relationship for glycopeptides and lipopeptides
resulted in a positive correlation for all agent
combinations. In time–kill evaluations, CPT
demonstrated greater reductions in log10
colony-forming unit (CFU)/mL against mutant
strains (3.73 ± 0.67) versus parents
(2.79 ± 0.75) despite no change in CPT MIC
(P = 0.112).
Conclusion: This study demonstrated a marked
‘‘seesaw effect’’ whereby CPT displayed
increased susceptibility as the VAN, DAP, and
TEI MICs increased. Additionally, we observed a
positive linear correlation between VAN, DAP,
and TEI MICs for all agent combinations.
Enhanced activity was noted with CPT in
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mutant strains versus the parent strains despite
no change in MIC. Based upon the enhanced
CPT activity observed against strains with
decreased susceptibility to VAN, DAP and TEI,
CPT may provide an option for infections with
reduced susceptibility to glycopeptides or
lipopeptides. Further evaluation is warranted
to investigate the clinical implications of the
seesaw effect.
Keywords: Ceftaroline; Daptomycin; hVISA;
Infection; MRSA; Seesaw effect; Staphylococcus
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INTRODUCTION
Staphylococcus aureus continues to be a major
healthcare threat. Methicillin-resistant S. aureus
(MRSA) demonstrating reduced susceptibility to
glycopeptides and lipopeptides such as
vancomycin (VAN), teicoplanin (TEI), and
daptomycin (DAP) severely limits our
therapeutic options for treating complicated
infections due to this pathogen. MRSA now
comprises 55.5% of hospital-acquired S. aureus
infections [1, 2]. MRSA with reduced
susceptibility to glyco- and lipopeptide
antibiotics is increasingly being reported.
Infections caused by MRSA isolates with
reduced VAN susceptibility often lead to worse
clinical outcomes, especially in strains
identified as VAN-intermediate S. aureus
(VISA), heterogeneous VISA (hVISA), or DAP
non-susceptible (DNS) [3–10]. However,
relatively few new antimicrobial agents are
available, necessitating alternative treatment
strategies including combination therapies and
dose optimization as well as maximization of
older antimicrobials. One newer strategy is
based on the ‘‘seesaw effect’’, whereby b-lactam
susceptibility increases as glyco- and
lipopeptide susceptibility decreases, allowing
for older beta-lactam antimicrobials to be used
in combination with glycopeptides or
lipopeptide antibiotics such as VAN and DAP
or the anti-MRSA cephalosporin ceftaroline
(CPT) [11, 12]. However, this phenomenon has
only been evaluated on a limited number of
strains [12–16]. Therefore, the objective of this
study was to further explore the ‘‘seesaw effect’’
in 150 clinical strains with varying
susceptibilities. Additionally, eight strains were
utilized in time–kill studies to determine if the
response to CPT was affected by changing glyco-




A total of 150 clinical MRSA strains from the
Anti-infective Research Laboratory (Detroit,
MI, USA) collected between 2008 to 2012
were chosen for evaluation of the ‘‘seesaw
effect’’. All strains were randomly chosen
clinical blood isolates. Additionally, four
isogenic strain pairs were selected for further
evaluation of these antibiotics in time–kill
curves to compare differences in kill between
parent and reduced susceptibility to VAN
mutant isolates.
Antimicrobials
Ceftaroline (Teflaro) powder was provided by
Forest Laboratories, Inc. (New York, NY, USA).
DAP (Cubicin) was purchased commercially
from Cubist Pharmaceuticals (Lexington, MA,
USA). VAN and TEI were purchased
commercially from Sigma Chemical Co. (St.
Louis, MO, USA).
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Media
Due to the calcium-dependent mechanism of
DAP, MHB was supplemented with 50 mg/L of
calcium and 12.5 mg/L of magnesium for all
experiments. Colony counts were determined
using tryptic soy agar (TSA) (Difco, Detroit, MI,
USA).
Susceptibility Testing
Minimum inhibitory concentrations (MIC) for
all study antimicrobials were determined by
Etest methods according to the manufacturer’s
instructions. Additionally, broth microdilution
MICs were performed in duplicate at 1 9 106
according to Clinical and Laboratory Standards
Institute (CLSI) guidelines for isogenic strain
pairs as a comparison/validation of MICs
determined by Etest methodology [18]. All
samples were incubated at 37 C for 18–24 h.
The following MIC data were determined for
each tested antimicrobial: average MIC, MIC50,
and MIC90. These MIC data were analyzed by
linear regression to derive correlations
coefficients between agents.
In Vitro Time–Kills
Four isogenic strain pairs were chosen as
representative strains for evaluation in time–
kill curves. Briefly, macro-dilution time–kill
experiments were performed in duplicate
using a starting inoculum of approximately
1 9 106 CFU/mL as previously described [17–
19]. The 24-well culture plate was utilized with
100 lL of antibiotic stock solution, 200 lL of a
1:10 dilution of a 0.5 McFarland standard
organism suspension, and sufficient volume of
CAMHB for a total volume of 2 mL. Sample
aliquots (0.1 mL) were removed over 0–24 h
and serially diluted in cold 0.9% sodium
chloride. Bacterial counts were determined
using an automatic spiral plater (WASP; DW
Scientific, West Yorkshire, UK) and colonies
were enumerated using the protocol colony
counter (Synoptics Limited, Frederick, MD,
USA). If the anticipated dilution was near the
MIC, vacuum filtration was used to avoid
antibiotic carryover. Filtered samples were
washed through a 0.45-lm filter with normal
saline to remove the antimicrobial agent. For
both methods, plates were incubated at 37 C
for 18–24 h at which time colony counts were
performed. These methods have a lower limit
of reliable detection of 1 log10 CFU/mL.
Each isolate (parent and mutant) was tested
against CPT, DAP, VAN, and TEI at the
following human-simulated pharmacokinetic
concentrations: free DAP peak 4.6 mg/L
(equivalent to 4 mg/kg/day, 92% protein
binding), free CPT midpoint concentration
3.5 mg/L (equivalent to 600 mg every 12 h;
20% protein binding), free VAN 7.5 mg/L
(equivalent to 15 mg/L trough; 50% protein
binding), and TEI trough 2 mg/L (equivalent to
20 mg/L trough; 90% protein binding). Time–
kill curves were graphed plotting the mean
colony counts (log10 CFU/mL) versus time.
Bactericidal activity was defined as C3 log10
CFU/mL (99.9%) reduction from the starting
inoculum. Bacteriostatic activity is defined as a
0 to \3-log10 CFU/mL reduction in colony
count from the initial inoculum.
Statistical Analysis
Differences in log10 CFU/mL were analyzed by
analysis of variance with Tukey’s post hoc test.
Correlation coefficients were determined via
Spearman’s rho testing. P\0.05 was
considered significant. All statistical analyses
were performed using SPSS statistical software
(release 21.0; SPSS, Inc., Chicago, IL, USA).
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RESULTS
A summary of MIC data is listed in Table 1.
There was a large range of susceptibilities noted
for each antimicrobial with DAP, TEI, and VAN
having the largest range of susceptibilities.
Positive MIC correlations were found between
all glyco- and lipopeptides, VAN, DAP, and TEI.
Inverse MIC correlations were found between
CPT and all other agents. The correlation
coefficients are listed in Table 2. MICs for the
isogenic strains are listed in Table 3. In three of
four pairs (D592 and D712, R6911 and R6913,
A8090 and A8091), CPT activity was
significantly more active against MRSA strains
with reduced glycopeptide susceptibility despite
the mutant strains having the same CPT MIC as
the parent strains (P = 0.007, 0.001, 0.045).
Against the 4th strain pair (R6491 and R6387),
CPT demonstrated slightly improved activity
against the mutant strain with a
4.3 ± 0.3 log10 CFU/mL reduction versus
3.76 ± 0.3 log10 CFU/mL reduction observed
for the parent, though this was not statistically
significant (P = 0.318). Overall, CPT
demonstrated greater activity against all
mutant strains with an average of
3.73 ± 0.67 log10 CFU/mL reduction in mutant
strains versus 2.79 ± 0.75 log10 CFU/mL








CPT 0.125–1.5 0.38 1
DAP 0.03–4 0.25 2
TEI 0.25–16 1.5 8
VAN 0.19–8 1 6
CPT ceftaroline, DAP daptomycin, TEI teicoplanin, VAN
vancomycin








MIC90 -0.912* -0.963* -0.936*
MIC50 -0.858* -0.847* -0.818*
MIC -0.535* -0.386* -0.483*
DAP
MIC90 0.943* 0.947* –
MIC50 0.959* 0.957* –
MIC 0.666* 0.632* –
TEI
MIC90 0.971* – –
MIC50 0.997* – –
MIC 0.789* – –
CPT ceftaroline, DAP daptomycin, MIC minimum
inhibitory concentration, TEI teicoplanin, VAN
vancomycin
* P\0.05
Table 3 Minimum inhibitory concentrations for isogenic
strain pairs
Strain pairs MICs (mg/L) parent/mutant
CPT DAP TEI VAN
R6911/R6913 0.5/0.5 2/4 4/4 2/8
R6491/R6387 1/1 0.5/0.5 0.125/4 1/2
D592/D712 1/1 0.5/4 0.5/2 2/4
A8090/A8091 0.5/0.5 0.25/1 0.5/4 1/8
CPT ceftaroline, DAP daptomycin, TEI teicoplanin, VAN
vancomycin
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reduction for the parent strains with no change
in CPT susceptibility noted (P = 0.112) as
illustrated in Fig. 1. DAP demonstrated potent
bactericidal activity against all susceptible
strains with a log10 CFU/mL decrease of
3.5 ± 0.8 log10 CFU/mL. A bactericidal effect
was also noted for two mutant strains (D712
and A8091). However, after the initial kill
within the first 8 h, significant regrowth of 1.5
log10 CFU/mL increase from starting inoculum
occurred in the other two mutants. VAN
demonstrated activity against all parent
isolates within the first 8 h, but kill was not
sustained over the complete duration of the
experiment against R6491. Against R6387, VAN
demonstrated bacteriostatic activity with
Fig. 1 Time–kill evaluation results. Closed circles ceftaroline, open triangles daptomycin, closed triangles teicoplanin, open
diamonds vancomycin, closed squares drug-free control
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2.3 ± 0.1 log10 CFU/mL reduction, but no
appreciable activity was noted against any of
the other mutants. TEI only displayed activity
against one of the eight strains tested (A8090)
with 2.4 ± 0.1 log10 CFU/mL reduction over
24 h. All remaining strains with TEI
demonstrated minimal to no activity (0–\1
log10 CFU/mL reduction).
DISCUSSION
The results of this study demonstrate that as the
VAN MIC increased, a linear increase in MIC
was also observed for DAP and TEI. This positive
correlation was more pronounced with the two
glycopeptides, but was only slightly less for
DAP. Although not previously reported with
Fig. 1 continued
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TEI, we observed the same ‘‘seesaw effect’’ with
TEI that has previously been demonstrated with
VAN and DAP [15]. Additionally, the CPT MIC
appeared to decrease as the glyco- and
lipopeptide MIC increased. In our time–kill
evaluations, CPT was more active against
isolates with reduced susceptibility to glyco-
and lipopeptide antimicrobials than to the
parent strains. Of note, the CPT MIC did
remain the same from parent to mutant, while
the MIC for the other agents increased. For the
parent isolates, CPT demonstrated consistent
kill compared to mutants, though DAP
appeared to have the most pronounced
activity for all parent isolates.
The ‘‘seesaw effect’’ was first reported as a
laboratory phenomenon by Sieradzki and
colleagues [16]. The parent isolate, COL, had a
methicillin MIC of 800 mg/L with a VAN MIC of
1.5 mg/L; after exposing the isolate to in vitro
VAN pressure, MIC increased from 1.5 and
100 mg/L, respectively. The first clinical case
describing this type of effect was published
2 years later in a 79-year-old hemodialysis
patient with MRSA bacteremia [13]. Initial
isolates obtained demonstrated an oxacillin
MIC of 3 mg/L and a VAN MIC of 2 mg/L.
After continued VAN exposure and documented
sub-therapeutic VAN serum concentrations, the
VAN MIC increased to 8 mg/L whereas the
oxacillin MIC subsequently decreased to
0.8 mg/L. Similarly, a second case report was
published describing a similar effect in a patient
with MRSA-infective endocarditis [14]. This
patient received a prolonged course of VAN
therapy, and as therapy continued the VAN
MIC increased from 1 to 8 mg/L while the
oxacillin MIC decreased from as high as 100 to
0.75 mg/L.
Additional research on this phenomenon
has been carried out utilizing
pharmacokinetic/pharmacodynamics in vitro
modeling. Werth and colleagues [15]
performed in vitro studies evaluating three
isogenic S. aureus strain pairs, including DNS
and VISA strains exposed to human-simulated
concentrations of CPT and VAN. In all three
pairs, CPT activity was significantly more active
against MRSA strains with reduced glycopeptide
susceptibility despite the mutant strains having
the same CPT MIC as the parent strains.
Though there are in vitro and in vivo data to
support the ‘‘seesaw effect’’, this is the first study
to evaluate such a large number of strains
including a significant number that are
unrelated (all strains except the 8 isogenic
strains). The sample of 150 isolates
demonstrated a seesaw pattern. These data
help to confirm the previous observations that
have been reported with a few clinical or
laboratory-derived strains.
As resistance has emerged to antibiotics such
as VAN and DAP, the seesaw effect may provide
an avenue for alternative therapeutic options.
The seesaw effect can also be further exploited
through combination therapy of a glyco- or
lipopeptide plus an anti-staphylococcal beta-
lactam. In the presence of an anti-
staphylococcal b-lactam, DAP binding is
increased leading to enhanced depolarization
despite increases in DAP MIC [11, 20].
Limitations
Potential limitations for this investigation include
the evaluation of a limited number of strains and
antibiotic combinations utilized in the time–kill
curve assessments. Additionally, time–kill curve
methodology only utilizes fixed concentration
exposures. To further elicit additional impact,
multiple dose pharmacokinetic modeling would
need to be analyzed.
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CONCLUSION
In 150 isolates, it was evident that CPT MICs
decreased as VAN, TEI, and DAP MICs
increased. After additional testing on eight
isogenic strains, enhanced CPT killing was
observed in the strains with decreased
susceptibility to VAN, DAP, and TEI. CPT may
provide clinicians with a therapeutic alternative
due to enhanced activity when faced with
MRSA isolates with elevated glyco- or
lipopeptide MICs, such as hVISA, VISA, or
DNS strains. However, additional research is
warranted to determine the clinical utility of
this phenomenon.
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